Floatz logo

LY3143921

D. Squamous Carcinoma of the Oesophagus

Cancer Research UKSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

64 Active assets in the D. Squamous Carcinoma of the Oesophagus cohort.

Asset / SponsorPhaseRating
Eloxatin
Taiho Oncology, Inc.
Phase 3BB
FLUOROURACILUM
AstraZeneca
Phase 3BB
Levoleucovorin
Taiho Oncology, Inc.
Phase 3BB
Irinotecan
Taiho Oncology, Inc.
Phase 2BB
Cetuximab
Hummingbird Bioscience
Phase 2B

View all 50 →

Same molecule, other indications

LY3143921 is also rated in:

ovarian serous cystadenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell squamous lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →